Cargando…

Predictive value of ACE I/D genetic polymorphism for 12-month all-cause mortality in patients with acute myocardial infarction

The prognostic role of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) genetic polymorphism in patients with acute myocardial infarction (AMI) is controversial and inconsistent across various study populations. This study evaluated the predictive validity of the ACE I/D variant base...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Duy Cong, Do, Minh Duc, Le, Linh Hoang Gia, Thai, Truc Thanh, Hoang, Sy Van, Truong, Binh Quang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476856/
https://www.ncbi.nlm.nih.gov/pubmed/37657040
http://dx.doi.org/10.1097/MD.0000000000034976
_version_ 1785101020275146752
author Tran, Duy Cong
Do, Minh Duc
Le, Linh Hoang Gia
Thai, Truc Thanh
Hoang, Sy Van
Truong, Binh Quang
author_facet Tran, Duy Cong
Do, Minh Duc
Le, Linh Hoang Gia
Thai, Truc Thanh
Hoang, Sy Van
Truong, Binh Quang
author_sort Tran, Duy Cong
collection PubMed
description The prognostic role of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) genetic polymorphism in patients with acute myocardial infarction (AMI) is controversial and inconsistent across various study populations. This study evaluated the predictive validity of the ACE I/D variant based on 12-month all-cause mortality in Vietnamese patients after AMI. This was an observational, prospective study conducted among AMI patients at Cho Ray Hospital between January 2020 and September 2021. All participants were identified for ACE I/D polymorphism using the polymerase chain reaction method, with follow-up on survival status at 12 months from the date of admission. The proportions of II, ID, and DD genotypes of the ACE I/D variant were 49.5%, 35.9%, and 14.6%, respectively. All-cause mortality after 12 months occurred in 58 cases (10.6%). The ACE I/D polymorphism did not affect all-cause mortality in the dominant (P = .196), recessive (P = .827), homozygous (P = .515), and heterozygous (P = .184) models. A subgroup analysis by usage status of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB) showed that in the non-ACEI/ARB group, patients with the DD genotype had a lower cumulative survival probability than patients with the II/ID genotypes (hazard ratio [HR] = 3.97, 95% confidence interval [CI]: 1.21–13.04; P = .023). Among patients with Global Registry of Acute Coronary Events (GRACE) scores below the median (153.5 points), those with DD genotype had a higher risk of mortality than those with the II/ID genotypes (HR = 3.35, 95% CI: 1.01–11.11; P = .049). The ACE I/D genetic polymorphism was found not to be associated with 12-month all-cause mortality in Vietnamese patients with AMI. However, it was associated with mortality in patients who did not use ACEI/ARB and also whose GRACE scores were below 153.5 points.
format Online
Article
Text
id pubmed-10476856
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104768562023-09-05 Predictive value of ACE I/D genetic polymorphism for 12-month all-cause mortality in patients with acute myocardial infarction Tran, Duy Cong Do, Minh Duc Le, Linh Hoang Gia Thai, Truc Thanh Hoang, Sy Van Truong, Binh Quang Medicine (Baltimore) 3400 The prognostic role of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) genetic polymorphism in patients with acute myocardial infarction (AMI) is controversial and inconsistent across various study populations. This study evaluated the predictive validity of the ACE I/D variant based on 12-month all-cause mortality in Vietnamese patients after AMI. This was an observational, prospective study conducted among AMI patients at Cho Ray Hospital between January 2020 and September 2021. All participants were identified for ACE I/D polymorphism using the polymerase chain reaction method, with follow-up on survival status at 12 months from the date of admission. The proportions of II, ID, and DD genotypes of the ACE I/D variant were 49.5%, 35.9%, and 14.6%, respectively. All-cause mortality after 12 months occurred in 58 cases (10.6%). The ACE I/D polymorphism did not affect all-cause mortality in the dominant (P = .196), recessive (P = .827), homozygous (P = .515), and heterozygous (P = .184) models. A subgroup analysis by usage status of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB) showed that in the non-ACEI/ARB group, patients with the DD genotype had a lower cumulative survival probability than patients with the II/ID genotypes (hazard ratio [HR] = 3.97, 95% confidence interval [CI]: 1.21–13.04; P = .023). Among patients with Global Registry of Acute Coronary Events (GRACE) scores below the median (153.5 points), those with DD genotype had a higher risk of mortality than those with the II/ID genotypes (HR = 3.35, 95% CI: 1.01–11.11; P = .049). The ACE I/D genetic polymorphism was found not to be associated with 12-month all-cause mortality in Vietnamese patients with AMI. However, it was associated with mortality in patients who did not use ACEI/ARB and also whose GRACE scores were below 153.5 points. Lippincott Williams & Wilkins 2023-09-01 /pmc/articles/PMC10476856/ /pubmed/37657040 http://dx.doi.org/10.1097/MD.0000000000034976 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 3400
Tran, Duy Cong
Do, Minh Duc
Le, Linh Hoang Gia
Thai, Truc Thanh
Hoang, Sy Van
Truong, Binh Quang
Predictive value of ACE I/D genetic polymorphism for 12-month all-cause mortality in patients with acute myocardial infarction
title Predictive value of ACE I/D genetic polymorphism for 12-month all-cause mortality in patients with acute myocardial infarction
title_full Predictive value of ACE I/D genetic polymorphism for 12-month all-cause mortality in patients with acute myocardial infarction
title_fullStr Predictive value of ACE I/D genetic polymorphism for 12-month all-cause mortality in patients with acute myocardial infarction
title_full_unstemmed Predictive value of ACE I/D genetic polymorphism for 12-month all-cause mortality in patients with acute myocardial infarction
title_short Predictive value of ACE I/D genetic polymorphism for 12-month all-cause mortality in patients with acute myocardial infarction
title_sort predictive value of ace i/d genetic polymorphism for 12-month all-cause mortality in patients with acute myocardial infarction
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476856/
https://www.ncbi.nlm.nih.gov/pubmed/37657040
http://dx.doi.org/10.1097/MD.0000000000034976
work_keys_str_mv AT tranduycong predictivevalueofaceidgeneticpolymorphismfor12monthallcausemortalityinpatientswithacutemyocardialinfarction
AT dominhduc predictivevalueofaceidgeneticpolymorphismfor12monthallcausemortalityinpatientswithacutemyocardialinfarction
AT lelinhhoanggia predictivevalueofaceidgeneticpolymorphismfor12monthallcausemortalityinpatientswithacutemyocardialinfarction
AT thaitructhanh predictivevalueofaceidgeneticpolymorphismfor12monthallcausemortalityinpatientswithacutemyocardialinfarction
AT hoangsyvan predictivevalueofaceidgeneticpolymorphismfor12monthallcausemortalityinpatientswithacutemyocardialinfarction
AT truongbinhquang predictivevalueofaceidgeneticpolymorphismfor12monthallcausemortalityinpatientswithacutemyocardialinfarction